Dr. Bijal D. Shah, MD

Dr. Shah practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Shah's NPI, 1508023714, was assigned on May 16, 2008. Dr. Shah graduated from USF Health Morsani College of Medicine in 2004. Dr. Shah holds Florida license ME102874.

Dr. Shah's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Shah's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shah practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Shah's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Shah is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Shah's licenses on file in 2 states: Florida and North Carolina.

Dmand AI lists chronic leukemia, lymphoma and prostate cancer among the conditions Dr. Shah treats.

CMS data shows 264 Medicare services from Dr. Shah across 5 procedure codes in 2024, for 144 Medicare patients. Medicare paid $18,747 for them.

CMS counts 144 Medicare patients who saw Dr. Shah in 2024. The largest group is 65 to 74, with 69 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 10% are also on Medicaid. Their average risk score is 2.72, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shah's median patient age at 69, with 40% women.

In 2024, Dr. Shah wrote 274 Medicare Part D claims for 73 patients. 69% of them were for generic drugs. CMS names the drug for 206 of them, across 7 drugs with 11 or more claims each, at $1,235,452 in total drug cost. In 2023, CMS named 163 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Shah for performance year 2024, reported as part of a group. Dr. Shah accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Shah as offering telehealth.

Dmand AI links 110 papers to Dr. Shah, published from 2010 to 2025. 2023 was the busiest year, with 10. The most frequent topics are Immunotherapy, Adoptive, Lymphoma, Mantle-Cell and Antineoplastic Combined Chemotherapy Protocols. Dr. Shah has published most often in Transplant Cell Ther. Dr. Shah's most frequent co-authors are Julio C. Chavez, MD, Frederick Lundry Locke, MD and Taiga Nishihori, MD.

Dmand AI links Dr. Shah to 11 clinical trials, 4 of them phase 2 studies. Conditions studied include Burkitt Lymphoma, Leukemia, Myelomonocytic, Chronic and Precursor B-Cell Lymphoblastic Leukemia-Lymphoma. H. Lee Moffitt Cancer Center and Research Institute sponsors the most, 6.

CMS Open Payments shows 278 general payments to Dr. Shah from 31 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 63% of the total. Amgen Inc. paid the most, $35,246. It also lists 3 research payments totaling $6,324 from 2019 to 2024.

Dr. Shah graduated from USF Health Morsani College of Medicine in 2004.

Dr. Shah is in network with 9 carriers, including Aetna, Excellus BlueCross BlueShield and United Healthcare. HMO plans come from the most carriers, 7. Check the plan with the practice before a visit.